Catalyst Brief

← Calendar

Readoutin 45d

Pfizer — RSVpreF

Phase 3 primary completion: Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults..

Date
Jan 2027
Type
Readout
Indication
Lower Respiratory Tract Illness

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Pfizer

  1. Apr2027
  2. Feb2027
    Readoutin 76d
    Pfizer — PF-06821497
    Phase 3 primary completion: A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1)..